The results of a new clinical trial has determined that "the combination of all-trans retinoic acid, ...a metabolite of vitamin A and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL." The trial, conducted on 154 children between 1-22 years old who were recently diagnosed with standard or high-risk APL, showed 2-year event-free survival rates of 96%-98%, with fewer than 10% experiencing severe side effects.
To learn more about this trial, click here.
Study mentioned: Kutny MA, Alonzo TA, Abla O, et al. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia A Report From the Children’s Oncology Group AAML1331 Trial. JAMA Oncology November 11, 2021. DOI: 10.1001/jamaoncol.2021.5206.
No comments:
Post a Comment